Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.

ABSTRACT:

Aims

Clinical guidelines for breast cancer management have evolved in the past decade. However, limited evidence exists regarding uptake of novel drug classes in management of hormone receptor-positive (HR+) metastatic breast cancer (MBC) in the USA and whether disparities exist by race and ethnicity.

Methods

Using SEER-Medicare databases, we identified 4404 women aged ≥66 years diagnosed with HR+ de novo MBC (dnMBC) between 2010 and 2019. Age-standardized rates for receipt of first-line treatment were calculated. Age-adjusted rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Poisson regression to compare rates among non-Hispanic Black (NHB) and Hispanic patients with non-Hispanic White (NHW) patients.

Results

Among patients with HR+/human epid

SUBMITTER: Zhu K 

PROVIDER: S-EPMC12648379 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature